BAX vs HSIC

For growth investors, Baxter International Inc.

(BAX) is the stronger pick with 5. 7% revenue growth year-over-year, versus 4. 0% for Henry Schein, Inc. (HSIC). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Baxter International Inc. (BAX) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Baxter International Inc.

is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Henry Schein, Inc.

(HSIC) delivered a total return of -12. 5%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: HSIC returned +5. 3% versus BAX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Henry Schein, Inc.

(HSIC) is the lower-risk stock at 0. 73β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 87% more volatile than HSIC relative to the S&P 500. On balance sheet safety, Henry Schein, Inc. (HSIC) carries a lower debt/equity ratio of 77% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Baxter International Inc.

(BAX) is pulling ahead at 5. 7% versus 4. 0% for Henry Schein, Inc. (HSIC). On earnings-per-share growth, the picture is similar: Henry Schein, Inc. grew EPS 7. 2% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, BAX leads at 3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -2. 7% for BAX. At the gross margin level — before operating expenses — BAX leads at 30. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Baxter International Inc.

(BAX) trades at 9. 2x forward P/E versus 13. 3x for Henry Schein, Inc. — 4. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HSIC: 22. 6% to $86. 43.

In this comparison, BAX (3.

9% yield) pays a dividend. HSIC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Henry Schein, Inc.

(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Both have compounded well over 10 years (HSIC: +5. 3%, BAX: -42. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BAX is a small-cap income-oriented stock; HSIC is a small-cap quality compounder stock. BAX pays a dividend while HSIC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.